Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | PHASE2 | ACTIVE NOT_RECRUITING | 470 | — | — | Oct 23, 2025 | May 3, 2029 | Jun 3, 2026 | 269 | United States, Argentina +34 |
Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first)
Defined as the time from the randomization date to the date of death from any cause
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Arm C | PLACEBO_COMPARATOR | - |
| Arm D | PLACEBO_COMPARATOR | - |
| Arm E | EXPERIMENTAL | - |
| Arm F | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Navlimetostat | DRUG | Specified dose on specified days |
| Gemcitabine | DRUG | Specified dose on specified days |
| Nab-paclitaxel | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC). * Evidence of homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss detected in tumor tissue. * Metastatic disease with at least 1 measurable lesion a...